Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "Cell Counting Devices Market - Global Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The Global Cell Counting Devices Market was valued at USD 12.39 billion in 2023, and is expected to reach USD 18.64 billion by 2029, rising at a CAGR of 7.04%.
The development from manual to automated cell counting devices, integration and adoption of innovative technologies such as flow cytometry and image-based cell counting systems, and integration of new modules and tools are revolutionizing the cell counting devices market landscape and are expected to deliver significant growth opportunities. The most recent advancement, the introduction of image-based cell counters, delivers the benefits of continuous development of image analysis algorithms and machine learning for more consistent and faster counting. Certainly, computer-based image analysis helps detect features easily missed by the human eye. All these developments emerge rapidly as the industry develops with automated cell counting devices. These advanced systems lighten traditional methods' changeability, providing faster throughputs and superior accuracy.
Market Trends
- Increasing Application Areas for Cell Counting Devices
- Growing Burden of Chronic Disorders
INSIGHTS BY PRODUCT
The global cell counting devices market by product is segmented into consumables and instruments. The consumables segment holds the dominating segmental market share in 2023. The consumables in the cell counting procedures include assay, reagent, accessories, software analysis algorithms, assay kits, microplates, and accessories such as beads, slides, plates, and others. A broad range of consumables are used with cell counters that help optimize instrument setup, sampling preparation, and quality control. The application rate of cell-counting consumables is comparatively higher than that of instruments. Consumables are used and discarded, which demand continued investment that drives significant market growth.
The instrument segment includes spectrophotometers, flow cytometers, hematology analyzers, manual cell counters/hemocytometers, automated cell counters, and Coulter counters. Cell counting devices, including manual and automated ones, are considered instruments in the study report. The growth of the segment heavily relies on technological advancements in cell counters. The available automated cell counters offer more precision and reduce the work burden and human errors. The popularity of automated cell counters is accelerating segmental growth. Furthermore, automated cell counters offer higher throughput and become an alternative to other cell counter instruments; apart from that, the rising preference for flow cytometers, spectrophotometers, and Coulter counters positively influences segmental growth. The industry has many cell-counting devices, and they all work differently. The rising application areas for cell counters, from healthcare to breweries and dairy industries, have boosted the market share significantly.
Segmentation by Product
- Consumables
- Instruments
INSIGHTS BY APPLICATION
The global cell counting devices market by applications is segmented into research, development, & bioprocessing, clinical diagnostics, and other applications. The research, development, & bioprocessing segment holds the most significant share of the global market 2023. The rapidly growing research, development, and bioprocessing activities across the life sciences are accelerating segmental growth. Furthermore, the growing application of cell counters in the medical field across disease diagnosis and associated activities are some of the leading factors propelling clinical diagnostics segmental growth.
Segmentation by Applications
- Research, Development, & Bioprocessing
- Clinical Diagnostics
- Other Applications
INSIGHTS BY END-USERS
The global cell counting devices market by end-users is segmented into pharma & biotech companies, diagnostics laboratories, research institutes & labs, CDMOs & CROs, and others. By end-users, the pharma & biotech companies accounted for most of the segmental market share in 2023. Pharma and biotech companies that are highly investing in the R&D of novel drugs and therapies widely perform research studies. Cell counting devices play a major role in developing cell and gene-based therapies, regenerative medicines, advanced biologics, vaccines, and others that require the study of various cells, where cell counters are most commonly used by pharma & biotech companies.
Segmentation by End-Users
- Pharma & Biotech Companies
- Diagnostics Laboratories
- Research Institutes & Labs
- CDMOs & CROs
- Other End-users
GEOGRAPHICAL ANALYSIS
North America dominated the global cell counting devices market share, accounting for a global share of over 36% in 2023. The region is dominating the global market with the rise in the aging population, prevalence of chronic diseases, increasing healthcare expenditure, need for advanced healthcare, presence of well-established players, and a major shift towards automation in cell counting devices. Most importantly, several manufacturers producing automated cell counting equipment with a wide range of products according to the margin of affordability contribute to the region's highest share in the global market. Furthermore, in North America, the U.S. is a major market landscape with the highest revenue growth for cell counting devices compared to other countries worldwide.
Europe holds a significant position in the global cell counting devices market in 2023. In Europe, a significant patient population with chronic diseases raises research and development activities across life sciences industries, delivering lucrative market growth opportunities. Furthermore, the growing research across cell and gene therapies, stem cells, and regenerative medicines drives the region's demand for automated cell counters. Also, APAC will likely be the fastest-growing region in the global cell counting devices market during the forecast period. This is mostly due to the growing aging population in need of diagnosis and treatment, the rise in prevalence of chronic diseases, demand for high-quality healthcare, growing healthcare infrastructure, and most importantly, the increasing number of healthcare centers such as hospitals, clinics, diagnostics centers, laboratories, and others.
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Russia
- Poland
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
- UAE
VENDOR LANDSCAPE
The global cell counting devices market is exceptionally active, with several global, regional, and local players offering various cell counters. Also, the hematology analyzers used for cell analysis and counting significantly influence vendor competition. Several leading hematology analyzer companies compete with cell counting device manufacturing companies. The market is increasingly competitive, and vendors are highly focused on making partnerships and collaborations to maintain a competitive edge over other players. For instance, in 2022, Merck KGaA made a research collaboration and commercial license agreement with Mersana Therapeutics to discover novel antibody-drug conjugates.
Key Company Profiles
- AbbottBusiness
- Bio-Rad Laboratories
- Boule
- Danaher
- Diatron
- HORIBA
- Merck KGaA
- PerkinElmer
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific
Other Prominent Vendors
- Advanced Instruments
- Agilent Technologies
- Axion BioSystems
- Aligned Genetics (Logos Biosystems)
- Alphatec Scientific
- Agappe Diagnostics
- Analyticon Biotechnologies
- Balio Diagnostics
- B&E BIO-TECHNOLOGY
- BioSystems Diagnostics
- Bioway Biological Technology
- BIOSYSY Scientific Devices GmbH
- Benchmark Scientific
- BD
- Bruker Spatial Biology (NanoString Technologies, Inc.)
- Bentley Instruments
- ChemoMetec
- Corning Incorporated
- Curiosis Inc
- Cytek Biosciences
- Cole-Parmer Instrument Company
- Cellular Technology Limited (Immunospot)
- CLINDIAG SYSTEMS
- CONTECH MEDICAL SYSTEMS
- Convergent Technologies
- CPC Diagnostics
- DIAGON
- Dirui
- Drucker Diagnostics
- DeNovix
- EDAN Instruments
- F. Hoffmann-La Roche
- Genrui Biotech
- High Technology
- Hospitex International Ltd.
- LINEAR CHEMICALS
- Maccura Biotechnology
- Meril Life Sciences
- Medsource Ozone Biomedicals
- NIHON KOHDEN CORPORATION
- Norma Instruments
- NanoEntek
- Paul Marienfeld GmbH & Co. KG
- RWD Life Sciences Co. Ltd.
- Revvity
- Sartorius AG
- Shenzhen Mindray Bio-Medical Electronics
- Shenzhen Landwind Industry
- Prestige Diagnostics
- SFRI
- Shenzhen Dymind Biotechnology
- Shenzhen Prokan Electronics
- SPINREACT
- Trivitron Healthcare
- Tecan Trading AG
- Tip Biosystems
Key Attributes
| Report Attribute | Details |
| No. of Pages | 317 |
| Forecast Period | 2023-2029 |
| Estimated Market Value (USD) in 2023 | $12.39 Billion |
| Forecasted Market Value (USD) by 2029 | $18.64 Billion |
| Compound Annual Growth Rate | 7% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/82ucl1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
